---
access_model:
  confidence: medium
  gated: none
  gated_source:
  - onboarding
  label: Open access
  onboarding: open
  pricing: unknown
  public: true
  source:
  - authentication
  - rate-limits
  - security
  trial: false
  try_now: false
agent_readiness:
  band: agent-aware
  dimensions:
    agent_card: false
    agent_skills: derived
    agentic_access: false
    agentic_commerce: false
    auth_clarity: bearer
    consent_identity: false
    delegated_identity: false
    dry_run_mode: false
    dynamic_client_registration: false
    error_semantics: documented
    event_surface_described: false
    idempotency: false
    mcp_server: false
    mcp_tool_quality: na
    openapi_examples: false
    operation_distinctiveness: na
    pagination_ratio: na
    protected_resource_metadata: false
    rate_limit_signal: documented
    reversibility_documented: false
    spec_presence: false
    well_known_catalog: false
  schema_version: '0.2'
  score: 8.8
  scored_at: '2026-11-06'
api_count: 1
apis:
- description: 'The public WordPress REST API (wp-json) of the MOMA Therapeutics website at momatx.com: the route index of the site''s content management system, catalogued as one site surface rather than as separate '
  name: MOMA Therapeutics Website (WordPress REST)
  slug: momatx-com-website-wordpress-rest
artifact_total: 8
common:
- group: company
  title: ''
  type: Website
  url: https://momatx.com/
- group: company
  title: ''
  type: About
  url: https://momatx.com/moma/
- group: other
  title: ''
  type: Science
  url: https://momatx.com/science/
- group: other
  title: ''
  type: Pipeline
  url: https://momatx.com/pipeline/
- group: other
  title: ''
  type: Team
  url: https://momatx.com/team/
- group: company
  title: ''
  type: News
  url: https://momatx.com/news-feed/
- group: company
  title: ''
  type: Blog
  url: https://momatx.com/posts/category/blog/
- group: company
  title: ''
  type: BlogRSS
  url: https://momatx.com/feed/
- group: operate
  title: ''
  type: PressReleases
  url: https://momatx.com/posts/category/press-release/
- group: company
  title: ''
  type: Careers
  url: https://momatx.com/join-us/
- group: commercial
  title: ''
  type: PrivacyPolicy
  url: https://momatx.com/privacy-policy/
- group: commercial
  title: ''
  type: TermsOfService
  url: https://momatx.com/terms/
- group: company
  title: ''
  type: LinkedIn
  url: https://www.linkedin.com/company/momatx
- group: company
  title: ''
  type: Twitter
  url: https://twitter.com/moma_tx
- group: learn
  title: ''
  type: YouTube
  url: https://www.youtube.com/channel/UCqBg_d0f0IqXUDbzADjcI1g
- group: other
  title: ''
  type: SecondaryMarket
  url: https://forgeglobal.com/moma-therapeutics_stock/
- group: auth
  href: https://artifacts.apis.io/moma-therapeutics/authentication/moma-therapeutics-authentication.yml
  title: ''
  type: Authentication
  url: authentication/moma-therapeutics-authentication.yml
- group: design
  href: https://artifacts.apis.io/moma-therapeutics/conventions/moma-therapeutics-conventions.yml
  title: ''
  type: Conventions
  url: conventions/moma-therapeutics-conventions.yml
- group: design
  href: https://artifacts.apis.io/moma-therapeutics/conformance/moma-therapeutics-conformance.yml
  title: ''
  type: Conformance
  url: conformance/moma-therapeutics-conformance.yml
- group: design
  href: https://artifacts.apis.io/moma-therapeutics/errors/moma-therapeutics-problem-types.yml
  title: ''
  type: ErrorCatalog
  url: errors/moma-therapeutics-problem-types.yml
- group: design
  href: https://artifacts.apis.io/moma-therapeutics/lifecycle/moma-therapeutics-lifecycle.yml
  title: ''
  type: Lifecycle
  url: lifecycle/moma-therapeutics-lifecycle.yml
- group: design
  href: https://artifacts.apis.io/moma-therapeutics/data-model/moma-therapeutics-data-model.yml
  title: ''
  type: DataModel
  url: data-model/moma-therapeutics-data-model.yml
- group: build
  href: https://artifacts.apis.io/moma-therapeutics/packages/moma-therapeutics-packages.yml
  title: ''
  type: Packages
  url: packages/moma-therapeutics-packages.yml
- group: auth
  href: https://artifacts.apis.io/moma-therapeutics/security/moma-therapeutics-domain-security.yml
  title: ''
  type: DomainSecurity
  url: security/moma-therapeutics-domain-security.yml
- group: operate
  href: https://artifacts.apis.io/moma-therapeutics/rate-limits/moma-therapeutics-rate-limits.yml
  title: ''
  type: RateLimits
  url: rate-limits/moma-therapeutics-rate-limits.yml
- group: commercial
  href: https://artifacts.apis.io/moma-therapeutics/plans/moma-therapeutics-plans-pricing.yml
  title: ''
  type: Plans
  url: plans/moma-therapeutics-plans-pricing.yml
- group: agent
  href: https://artifacts.apis.io/moma-therapeutics/llms/moma-therapeutics-llms.txt
  title: ''
  type: LLMsTxt
  url: llms/moma-therapeutics-llms.txt
- group: agent
  href: https://artifacts.apis.io/moma-therapeutics/skills/_index.yml
  title: ''
  type: AgentSkill
  url: skills/_index.yml
created: '2026-08-26'
description: 'MOMA Therapeutics is a Cambridge, Massachusetts drug-discovery company founded in 2020 that builds precision medicines against molecular machines — the highly dynamic proteins that convert chemical energy stored in cells into regulatory work such as protein transport, DNA repair and degradation, and whose constant conformational shape-shifting has historically made them undruggable. Its proprietary KNOMATIC platform combines advanced structural frameworks and functional-genomics target validation with high-throughput fragment and DNA-encoded-library screening, CRISPR gene editing, artificial intelligence for detecting dynamic conformational patterns, and machine-learning lead optimisation, all built against a continually expanding structure-function knowledge base. The company launched in April 2020 with an $86 million Series A led by Third Rock Ventures, added a $150 million Series B in May 2022, and has taken two wholly owned oncology assets into the clinic: MOMA-313, a selective
  inhibitor of the polymerase theta (Polθ) helicase domain for homologous- recombination-deficient tumours, which entered Phase 1 in August 2024; and MOMA-341, a potent and selective WRN helicase inhibitor for microsatellite-unstable and TA-repeat-expanded tumours, which dosed its first Phase 1 patient in July 2025. It also runs a five-year discovery collaboration with Roche announced in January 2024, an oncology collaboration and licence agreement with Bayer signed in October 2024, and an exclusive licence for a selective PARP1 inhibitor announced in January 2025. MOMA Therapeutics runs no developer program and publishes no product API, developer portal, API reference or machine-readable specification. The only machine-readable surface reachable without credentials is the WordPress REST content API behind momatx.com, catalogued here.'
image: https://momatx.com/wp-content/uploads/2025/03/logo-moma.png
layout: provider
modified: '2026-08-26'
name: MOMA Therapeutics
nav: Providers
network: true
overview: 'MOMA Therapeutics is listed with 1 API on the [APIs.io](https://apis.io/) network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Oncology.


  MOMA Therapeutics'' developer surface includes product news, engineering blog, YouTube channel, authentication, and 24 more developer resources.'
plans:
- name: Moma Therapeutics Plans Pricing
  plan_count: 0
  slug: moma-therapeutics-plans-pricing
random_paper: 16
rate_limits:
- limit_count: 0
  name: Moma Therapeutics Rate Limits
  slug: moma-therapeutics-rate-limits
score:
  band: emerging
  composite: 17.3
  coverage:
    artifact_dirs: 20
    catalog_earned: 32.0
    catalog_earned_first_party: 0.0
    catalog_gap: 83.0
    catalog_max: 115.0
    note: 'Disclosure, not a penalty. catalog_gap is rubric points API Evangelist could add with no action by this provider, and it is NOT subtracted from the composite above. It is our backlog EXCEPT where this provider already did the work: catalog_earned is how much of the class was satisfied at all, and catalog_earned_first_party how much of that came from artifacts the provider published rather than ones we generated (roadmap#221). catalog_earned_first_party is a FLOOR, not the whole share: only ~40 of the rubric''s 113 checks carry a provenance class at all, so a check we cannot attribute counts toward neither side. Read it as "at least this much was theirs", never as "the rest was ours".'
  delta: -1.0
  facets:
    access_clarity: 21.1
    contract_governance: 18.2
    contract_quality: 0.0
    developer_ergonomics: 20.8
    discoverability: 58.0
    operational_transparency: 0.0
  previous_composite: 18.3
  provenance:
    conformance: first-party
    mcp: derived
    skills: derived
  regulatory:
    applies: true
    matched_via: tags
    regime: Health
    regime_id: health
    score: 18.4
  schema_version: 0.27.0
  scored_at: '2026-11-06'
  trend: flat
  upsert:
    applies: false
    note: 'Not scored: no parseable contract to read. Never-measured is not the same fact as measured-empty, so this is absent rather than zero.'
    reason: no_specs
screenshot: https://apis.io/screenshots/moma-therapeutics/moma-therapeutics-2026-09-02T150619.png
security:
- kind: authentication
  name: Moma Therapeutics Authentication
  slug: moma-therapeutics-authentication
  summary_line: 0 schemes
- kind: domain-security
  name: Moma Therapeutics Domain Security
  slug: moma-therapeutics-domain-security
  summary_line: TLSv1.3 · DMARC
skill_count: 3
skills:
- name: moma-therapeutics-harvest-publications
  slug: moma-therapeutics-harvest-publications
- name: moma-therapeutics-resolve-people
  slug: moma-therapeutics-resolve-people
- name: moma-therapeutics-track-news-archive
  slug: moma-therapeutics-track-news-archive
slug: moma-therapeutics
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Oncology
- Precision Medicine
- Life Sciences
- Structural Biology
- Machine Learning
- content-api
website: https://momatx.com/
---
